Conmed Stock

Conmed EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Conmed (CNMD) as of Aug 12, 2026 is 10.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 5.25 — a change of 96.01% (higher).

EV/EBIT

10.28

YoY

96.01%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Conmed is 2026 10.28 . EV/EBIT (Enterprise Value to EBIT) of Conmed was 2025 5.25 . It decreases by 96.01% higher compared to the previous year.

The Conmed EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
43.12 base
Jan 1, 2020
72.88 base
Jan 1, 2021
42.78 base
Jan 1, 2022
39.14 base
Jan 1, 2023
28.60 base
Jan 1, 2024
10.63 base
Jan 1, 2025
12.33 base
Jan 1, 2026 (e)
8.48 base
YEARPRICE-TO-EBIT
2026 est 8.48
2025 12.33
2024 10.63
2023 28.60
2022 39.14
2021 42.78
2020 72.88
2019 43.12
2018 26.02
2017 30.73
2016 32.81
2015 23.99
2014 23.64
2013 21.11
2012 12.31
2011 86.96
2010 13.08
2009 23.52
2008 9.23
2007 8.17
2006 -140.57
Access this data via the Eulerpool API

Conmed Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Conmed's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Conmed's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Conmed's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Conmed grows earnings faster than its peers.

Conmed Stock analysis

What does Conmed do? Conmed Corporation is a leading medical technology company that offers a wide range of surgical instruments and devices for the fields of gastroenterology, endoscopy, orthopedics, gynecology, and electro surgery. The company was founded in 1970 and is headquartered in Utica, New York. The history of Conmed Corp began with the founding of Consolidated Medical Equipment, Inc. (CME) in 1970. The company initially started its business with the distribution of surgical instruments and devices for medical applications and quickly expanded in this field. In the 1980s, the company went public. In the 1990s, the company changed its name to Conmed Corporation and expanded its activities into the field of electro surgery, which has since become a major growth driver for the company. Today, Conmed Corp operates multiple manufacturing facilities worldwide and has sales offices in over 50 countries. The company is divided into four main business segments: gastroenterology, endoscopy, orthopedics, and electro surgery. The gastroenterology segment includes products for the diagnosis and treatment of gastrointestinal disorders, such as endoscopes, biopsy instruments, dilation balloons, trocars, and shears. In the endoscopy segment, Conmed Corp offers products for the diagnosis and treatment of digestive tract disorders, including endoscopes, biopsy instruments, dilation balloons, trocars, and shears. The orthopedics segment includes a wide range of surgical instruments and devices for the treatment of musculoskeletal disorders, including implants, bandages, bone plates, intramedullary nails, and others. Finally, the electro surgery segment is the fastest-growing segment of Conmed Corp and includes a wide range of devices for precision surgery, including electrocautery, electro surgery, endoscopy, and laparoscopy devices. Conmed Corp aims to develop innovative medical technologies that meet the needs of patients and healthcare professionals. The company places great emphasis on producing high-quality products that are reliable and safe. Conmed Corp is a successful company that continues to evolve and expand its product range to meet the rapidly evolving needs of the medical community. Conmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Conmed stock

EV/EBIT (Enterprise Value to EBIT) of Conmed is 10.28 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Conmed changed from 5.25 to 10.28, representing a 96.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Conmed since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Conmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Conmed

All Key Metrics — Conmed